hotspot -WSS

hotspot

author：explore 2025-09-29 21:25:40 - browse：41775

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Novel spinal cord stimulator treats paralysis without surgery

WSS

Maker of FluMist seeks to allow at

Why Sanofi got shellacked over its spinoff

The FDA weighs the risks of candy

Deliver public health messages at the right time

Meta's Zuckerberg and Chan on track to put $50 billion into science

Paying for Covid pills will soon shift to insurers

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Cancer drug shortages should be causing more outrage

Empower primary care with adequate payments and technology

FDA approval of Sarepta Duchenne genetic therapy gives me hope

BIO to announce reorganization, senior leaders expected to depart

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medtronic CEO on promising devices for diabetes, hypertension

Affirmative action in medical school literally saved lives

PBM executives asked to testify by House panel

In Memoriam: Notable people who died in 2023

The FDA weighs the risks of candy

hotspot

Senate panel to vote on hospitals, PBMs, prisoner care

Black vets could get higher VA benefits if race not used in lung test

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Novel spinal cord stimulator treats paralysis without surgery

Readout Newsletter: What happened with Sarepta's Duchenne data

The effects of a landmark ruling on DNA ownership are becoming clearer

hotspot

entertainment

Wikipedia

Wikipedia